Navigation Links
Viral Therapy Slows Pediatric Tumors in Mice
Date:2/15/2008

Treatment leaves healthy tissue unharmed while targeting solid masses, study finds

FRIDAY, Feb. 15 (HealthDay News) -- A laboratory-engineered virus can successfully slow the growth of two types of hard-to-treat pediatric tumors without harming healthy tissue, a new study shows.

The targeted viral therapy, dubbed rQT3, slowed neuroblastoma and peripheral nerve sheath tumors in mice, according to findings published in the Feb. 15 issue of Cancer Research. It also resulted in longer life spans in the mice compared with ones receiving just saline or other treatments for the tumors.

Neuroblastoma is the most common solid cancer tumor in childhood, most often striking those under age 5. Malignant peripheral nerve sheath tumors affect the connective tissue surrounding nerves.

Researchers at Cincinnati Children's Hospital Medical Center armed the oncolytic herpes simplex virus (oHSV)with a gene that steps up the body's work to block enzymes that aid the development and progression of certain cancers. Previous studies had shown oHSV can infect and kill human cancer cells without causing other harm or disease.

"Malignant solid tumors are still very difficult to treat effectively, especially without causing harm to normal tissues, so we need to find innovative therapeutic approaches," Dr. Timothy Cripe, a physician and researcher at Cincinnati Children's Hospital Medical Center, said in a prepared statement. "In our study, this tumor-targeting viral therapy enhanced anti-tumor activity by stimulating multiple biological processes, including directly killing the cancer cells and reducing the formation of blood vessels that fed the tumors. These data support continuing development and study of our tumor-targeted viral therapy to fight cancer."

The gene added to the virus carries instructions for a cancer-fighting protein, human tissue inhibitor of metalloproteinase 3 (TIMP3). TIMP3 blocks enzymes that aid the development and progression of cancer, called matrix of metalloproteinases (MMP).

MMPs help break down molecules that are important for the structural support and normal development of cells, organs and maintenance of tissues. However, when MMP activity becomes unbalanced, the enzyme plays a well-documented role in the formation of invasive and metastatic cancers, including pediatric neuroblastoma.

More information

The National Cancer Institute has more about childhood cancers.



-- Kevin McKeever



SOURCE: Cincinnati Children's Hospital Medical Center, news release, Feb. 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
2. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
3. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
4. MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study
5. Antivirals reduce deaths from flu in hospitalized patients
6. American Medical Association Clears Path for Adenoviral Conjunctivitis - Pink Eye - Detector
7. Is it pancreatitis in acute abdominal pain in acute viral hepatitis?
8. Mayo Clinic Proceedings article explores possible link between obesity and viral infections
9. Antiviral Wont Improve Bells Palsy Outcome
10. Key Viral Change Could Help Bird Flu Spread
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viral Therapy Slows Pediatric Tumors in Mice
(Date:2/10/2016)... ... 10, 2016 , ... Early this week, Team Iconic at J. Walter Thompson ... as the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé ... their product, through activities that focus on better farming, better lives and better cocoa. ...
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency ... find. Unfortunately, this can leave patients with dental emergencies at risk of losing a ... offering emergency dental care. , Common dental emergencies include:, , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ... reverse split of its issued and outstanding shares of ... Thursday, February 11, 2016. The Company,s common stock will ... 76303T308 and temporary ticker symbol "RCHAD". After 20 trading ... ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... 2016  Oxis International Inc. (OTC/QB: OXIS) announced today ... as a "clinical trial triumph" after one of the ... cancer remission. Daniel Vallera , a ... Center. --> Daniel Vallera , a ... Center. --> An article on the ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
Breaking Medicine Technology: